NUVB (Nuvation Bio Inc.) PDUFA Date | FDA Catalyst & Approval Status

Jul 22, 2026

Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

Nuvation Bio Inc. will host a conference call on August 6, 2026, to discuss its financial results for Q2 2026 and provide business updates. Investors and the public can access the live webcast and participate via a conference call. The company, founded in 2018, focuses on developing impactful cancer therapies.

Jul 20, 2026

▲ +7.9%on this newsshared move

Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma

Nuvation Bio has announced positive updated Phase 2 data for safusidenib, showing a confirmed objective response rate of 52% and a 36-month progression-free survival rate of 79%. The company is expanding its clinical program with two new studies: a Phase 3 study for newly diagnosed grade 2 glioma patients outside the U.S. and a Phase 2 study for patients whose glioma has progressed after treatment with vorasidenib in the U.S. The long-term data supports the efficacy and safety of safusidenib.

Jul 20, 2026

▲ +7.9%on this newsshared move

Comparative Efficacy of Taletrectinib Versus First-Generation TKIs in TKI-Naïve ROS1+ Non-Small Cell Lung Cancer: A Matching-Adjusted Indirect Comparison

The article discusses a study comparing the efficacy of Taletrectinib with first-generation TKIs in TKI-naïve ROS1+ non-small cell lung cancer. Using a matching-adjusted indirect comparison, the findings suggest that Taletrectinib may offer advantages over traditional therapies. This could impact treatment decisions for patients with this specific cancer type.

Jul 6, 2026

Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering

Nuvation Bio Inc. announced the full exercise of its Greenshoe option, raising an additional $37.5 million in a convertible senior notes offering, totaling $287.5 million. The company plans to use the net proceeds of approximately $277.6 million for general corporate purposes, including working capital and operating expenses. The offering was conducted under a registration statement with the SEC.

Jun 29, 2026

Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom

Nuvation Bio announced that the Medicines and Healthcare products Regulatory Agency in the U.K. has validated the Marketing Authorisation Application for taletrectinib, an oral treatment for advanced ROS1-positive non-small cell lung cancer. This follows a similar validation by the European Medicines Agency. Taletrectinib has already been approved in the U.S., China, and Japan, and aims to expand access for patients in the U.K.

Jun 26, 2026

Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes

Nuvation Bio has announced the pricing of an upsized offering of $250 million in convertible senior notes due in 2032. The offering, initially set at $200 million, is expected to close on June 30, 2026. Proceeds will be used to repay existing debt and for general corporate purposes. The notes will have a 0.75% interest rate and are convertible under specific conditions.

Jun 25, 2026

▼ -10.1%on this newsshared move

Nuvation Bio Announces Proposed Convertible Senior Notes Offering

Nuvation Bio has announced a proposed offering of $200 million in Convertible Senior Notes due in 2032, with an option for underwriters to purchase an additional $30 million. The proceeds will be used for various corporate purposes, including repaying existing loans. The offering is subject to market conditions and will include capped call transactions to mitigate potential dilution.

May 31, 2026

Patient-Reported Outcomes and Health-Related Quality of Life With Taletrectinib in Advanced ROS1+ NSCLC From the TRUST-II Study

The article discusses the findings from the TRUST-II study, which evaluated patient-reported outcomes and health-related quality of life for patients with advanced ROS1+ non-small cell lung cancer (NSCLC) treated with Taletrectinib. The results indicate that Taletrectinib may enhance the quality of life for these patients, showcasing its potential benefits in treatment satisfaction.

May 31, 2026

Randomized, Double-Blind, Phase 3 TRUST-IV Study of Adjuvant Taletrectinib vs Placebo in Patients With Stage IB–IIIA ROS1+ Non-Small Cell Lung Cancer (NSCLC)

The article discusses the Phase 3 TRUST-IV study, which evaluates Taletrectinib as an adjuvant treatment compared to placebo in patients with Stage IB–IIIA ROS1+ non-small cell lung cancer (NSCLC). This study aims to provide insights into the efficacy of Taletrectinib in improving patient outcomes. The randomized and double-blind nature of the study is designed to ensure unbiased results.

May 27, 2026

Nuvation Bio to Present at the Jefferies Global Healthcare Conference

Nuvation Bio Inc. will present at the Jefferies Global Healthcare Conference on June 3, 2026. CEO David Hung and CFO Philippe Sauvage will participate in a fireside chat, which will be available via live webcast. The company aims to address major challenges in cancer treatment with its diverse pipeline of therapies.

May 5, 2026

▲ +9.5%on this news

Nuvation Bio to Participate in Upcoming Investor Conferences

Nuvation Bio Inc. announced its participation in several upcoming investor conferences, including the Bank of America Securities Healthcare Conference and the H.C. Wainwright BioConnect Investor Conference. Key executives, including CEO David Hung and CFO Philippe Sauvage, will engage in fireside chats and one-on-one meetings. Live webcasts will be available on the company's website.

May 4, 2026

Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update Achieved $18.5 million in first quarter of 2026 net product revenues for IBTROZI (taletrectinib); majority of the approximately 200 p

Nuvation Bio reported strong financial results for the first quarter of 2026, with $18.5 million in net product revenues from IBTROZI, their ROS1 inhibitor. The company noted continued adoption in TKI-naïve patients and impressive long-term response durability exceeding four years. Additionally, Nuvation secured exclusive global rights to safusidenib, which is intended to advance the treatment options for IDH1-mutant glioma. Despite rising research and administrative costs, the company remains on a solid financial footing, with over $533 million in cash and assets.

Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers

Nuvation Bio announced that taletrectinib (IBTROZI) has been included in the NCCN Guidelines for CNS cancers as a recommended systemic therapy for ROS1-positive non-small cell lung cancer patients with brain metastases. This addition follows its previous recognition as a preferred agent for NSCLC. The drug has shown significant efficacy in treating brain metastases, highlighting its importance in addressing the needs of this patient population.

Apr 21, 2026

Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026

Nuvation Bio Inc. will host a conference call on May 4, 2026, to discuss its financial results and provide business updates for the first quarter of 2026. Investors and the public can participate via a live webcast or conference call. The company is dedicated to addressing significant challenges in cancer treatment with its diverse pipeline.

Mar 27, 2026

Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency

Eisai and Nuvation Bio have announced that the European Medicines Agency has validated their Marketing Authorisation Application for taletrectinib, a treatment for advanced ROS1-positive non-small cell lung cancer. This application follows approvals in the U.S., China, and Japan, with plans for additional filings in other regions. The companies aim to make this therapy available to patients in Europe, pending the review process.

Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Nuvation Bio reported strong financial results for Q4 and full year 2025, highlighting the successful launch of IBTROZI, which has rapidly gained adoption. The company also announced positive Phase 2 results for safusidenib in treating IDH1-mutant glioma. Despite a net loss of $36.6 million in Q4, Nuvation maintains a robust cash position of $529.2 million and is expanding its collaboration with Eisai to enhance global access to IBTROZI.

Feb 26, 2026

Nuvation Bio to Participate in Upcoming March 2026 Investor Conferences

Nuvation Bio Inc. has announced its participation in four upcoming investor conferences, including fireside chats and one-on-one meetings. Key executives, including CEO David Hung and CFO Philippe Sauvage, will represent the company. Live webcasts of the chats will be available on their website, with recordings accessible for 90 days post-event.

Feb 18, 2026

Nuvation Bio to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 2, 2026

Nuvation Bio Inc. will host a conference call on March 2, 2026, to discuss its financial results and business updates for the fourth quarter and full year of 2025. The event will be accessible to investors and the public via a live webcast. An archived recording will be available for 90 days post-event.

Feb 10, 2026

Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma

Nuvation Bio has announced a protocol amendment to its ongoing SIGMA trial, expanding it to a Phase 3 study. The trial will now include patients with grade 2 and 3 IDH1-mutant astrocytoma, as well as a new cohort for grade 3 oligodendroglioma. This expansion aims to address the significant unmet medical need for effective treatments in this patient population.

Dec 31, 2025

Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference Successfully started 216 patients on IBTROZI (taletrec

Nuvation Bio has reported preliminary financial results for Q4 2025, highlighting a successful launch of IBTROZI (taletrectinib) with 216 patients initiated during the quarter. The product generated approximately $15.7 million in net revenue for Q4 and $24.7 million since its launch. The company boasts a solid cash position of $529.2 million as it heads into 2026, where it aims to expand the reach of IBTROZI and progress its pipeline. However, the reported figures are preliminary and subject to future adjustments.

Nov 26, 2025

Forward-looking statements Certain statements included in this presentation (this "Presentation") that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United S

Nuvation Bio has released forward-looking statements regarding its clinical programs and drug developments, particularly focusing on IBTROZI and safusidenib. IBTROZI, a ROS1 inhibitor, was approved for advanced ROS1+ NSCLC, with an encouraging start marked by 204 new patient starts in Q3 2025. The company also has robust cash reserves that may lead to profitability without additional funding. However, the outlook also brings attention to inherent risks associated with clinical studies and drug commercialization.

Nov 3, 2025

DRIVEN BY SCIENCE FOCUSED ON LIFE November 2025 Forward-looking statements Certain statements included in this presentation (this "Presentation") that are not historical facts are forward-looking statements for purposes

Nuvation Bio has provided forward-looking statements regarding its ongoing and future clinical programs, specifically focusing on their products IBTROZI and safusidenib. IBTROZI, already approved in the U.S., Japan, and China, has shown promising patient uptake since its launch. The company also plans to amend the protocol for safusidenib’s pivotal study to include additional patient criteria, which could enhance its market position. Nuvation Bio's solid cash balance supports its strategic goals without immediate need for additional funding.

Nov 3, 2025

Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update Successfully started 204 patients on IBTROZI TM (taletrectinib) in the third quarter of 2025 Updated data continue to show IBTROZI's

Nuvation Bio reported its financial results for the third quarter of 2025, highlighting the successful enrollment of 204 patients on IBTROZI (taletrectinib), a treatment for advanced ROS1-positive non-small cell lung cancer. Updated data revealed a remarkable median duration of response of 50 months for IBTROZI as of August 2025. The company also announced progress in clinical trials for safusidenib and additional studies for IBTROZI. Despite a strong cash position of $549 million, Nuvation Bio reported a net loss of $55.8 million for the quarter, alongside increased operational expenses.

Aug 7, 2025

Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update Received U.S. Food and Drug Administration (FDA) approval for IBTROZI (taletrectinib), a next-generation oral treatment for advanced

Nuvation Bio announced positive financial results for Q2 2025, highlighted by the FDA approval of IBTROZI, an innovative treatment for advanced ROS1-positive non-small cell lung cancer (NSCLC). In just seven weeks post-approval, 70 patients began receiving IBTROZI. The company has a strong financial foundation with $607.7 million in cash. However, they reported a net loss of $59.0 million for the quarter, driven by increased administrative expenses.

May 7, 2025

Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update New Drug Application (NDA) for taletrectinib for advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) under U.S. Food an

Nuvation Bio has reported its first quarter 2025 financial results alongside a business update. The company is seeking FDA approval for taletrectinib, an oral ROS1 inhibitor for advanced NSCLC, with a PDUFA goal date set for June 23, 2025. Recent Phase 2 study results published affirm the drug's potential efficacy and safety profile. Despite a significant increase in net loss and R&D expenses, Nuvation maintains a strong financial position with substantial cash reserves.

Mar 6, 2025

Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update U.S. Food and Drug Administration (FDA) accepted and granted Priority Review to the New Drug Application (NDA) for tal

Nuvation Bio reported its financial results for Q4 and the full year of 2024, highlighting significant achievements including the FDA's acceptance of its New Drug Application for taletrectinib, with a PDUFA goal date set for June 23, 2025. The company announced a robust financial standing with $502.7 million in cash and marketable securities. They also launched an Expanded Access Program for taletrectinib while securing additional non-dilutive financing of up to $250 million. Despite these advancements, Nuvation Bio incurred a net loss of $49.4 million in the last quarter due to increased expenditures related to business expansion.

Nov 6, 2024

▲ +9.5%on this news· ran to +30% by day 3

Nuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business Update Submitted New Drug Application (NDA) for taletrectinib to the U.S. Food and Drug Administration (FDA) in October for the treatment of

Nuvation Bio reported its financial results for the third quarter 2024 and provided a business update, highlighting the submission of a New Drug Application for taletrectinib to the FDA for advanced ROS1-positive non-small cell lung cancer. The company presented encouraging data from pivotal Phase 2 studies at the ESMO Congress, suggesting high efficacy rates. Despite a significant financial loss this quarter and rising expenses attributed to its recent acquisition, Nuvation remains focused on its product pipeline and future clinical advancements. An experienced CFO has been appointed to strengthen the company's financial management.

Nuvation Bio Reports Second Quarter 2024 Financial Results and Provides Business Update Efficacy and safety data from the pivotal Phase 2 TRUST-I clinical study of taletrectinib, a ROS1 inhibitor, published in the Journa

Nuvation Bio announced its second quarter 2024 financial results and provided updates on its clinical pipeline. The company shared promising results from the Phase 2 TRUST-I study of taletrectinib, a ROS1 inhibitor, which showed favorable efficacy and safety data. Plans are in place to present more comprehensive data from both the TRUST-I and TRUST-II studies at upcoming conferences, supporting their application for regulatory approval in the U.S. Despite a notable financial loss this quarter, Nuvation Bio remains focused on advancing its drug candidates and exploring new indications for NUV-868.

Jun 20, 2024

ANHEART THERAPEUTICS LTD. (Incorporated in the Cayman Islands with limited liability) Report and Consolidated Financial Statements For the years ended

AnHeart Therapeutics Ltd. released its consolidated financial statements for the years 2023 and 2022, revealing substantial revenue growth yet significant losses. The company reported an increase in revenue from $10,211 in 2022 to $47,313 in 2023. However, the net loss also widened, which raised concerns regarding its financial health, with accumulated deficit climbing to $202,642. The financial statements, audited by Deloitte, confirmed a fair presentation of the company’s financial position.

May 14, 2024

Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update Acquisition of AnHeart Therapeutics transformed Nuvation Bio into a late-stage, global oncology company with potential to become a co

Nuvation Bio has reported its financial results for the first quarter of 2024, highlighting its successful acquisition of AnHeart Therapeutics, which positions the company as a late-stage player in oncology. The firm has also initiated a Phase 1/2 study for its drug-drug conjugate, NUV-1511, while maintaining a strong balance sheet with $597 million in cash. The company's research and development expenses have decreased, coinciding with progress in multiple clinical programs. Overall, Nuvation Bio aims to transition into a commercial organization by the end of 2025.

Mar 25, 2024

Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction Acquisition transforms Nuvation Bio into late-stage global oncology company with potential to become a commercial organization by the end of 2025 Acqu

Nuvation Bio has announced its acquisition of AnHeart Therapeutics in an all-stock transaction, aimed at enhancing its position in the oncology sector. The acquisition will add two promising therapies to Nuvation Bio's portfolio, including taletrectinib, a next-generation ROS1 inhibitor, and safusidenib, a mutant IDH1 inhibitor. This strategic move is expected to transform Nuvation Bio into a late-stage global oncology company, with the deal expected to close in the second quarter of 2024. The move not only strengthens its clinical pipeline but also maintains its robust cash position, avoiding the need for immediate capital raising.

Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Determined maximum tolerated dose (MTD) in Phase 1 monotherapy study of NUV-868; Phase 1b studies of NUV-868 in combin

Nuvation Bio reported its financial results for the fourth quarter and full year of 2023, highlighting successful progress in its pipeline, particularly with NUV-868 where the maximum tolerated dose was determined. The company also received FDA clearance for its IND application for NUV-1511 and maintained a strong financial position with $611.2 million in cash and marketable securities. Despite the accomplishments, Nuvation still faces significant losses, although these have decreased compared to the previous year. The company aims to build on its successes in 2024 with ongoing studies and new initiatives.

Nuvation Bio Reports Third Quarter 2023 Financial Results and Provides Business Update Phase 1 monotherapy study of NUV-868 and Phase 1b study of NUV-868 in combination with olaparib or enzalutamide are ongoing Expect to

Nuvation Bio (NUVB) reported its third quarter 2023 financial results, highlighting a focus on the clinical execution of its NUV-868 program for advanced solid tumors. The company maintains a solid cash position with $619.3 million as of September 30, 2023, despite reporting a net loss of $19.6 million. In addition to ongoing clinical trials for NUV-868, Nuvation Bio anticipates submitting an IND for its first Drug-Drug Conjugate clinical candidate by the end of 2023.

Aug 3, 2023

Nuvation Bio Reports Second Quarter 2023 Financial Results and Provides Business Update Enrollment ongoing in the Phase 1b study of NUV-868 in combination with olaparib or enzalutamide Enrollment ongoing in the Phase 1 m

Nuvation Bio Inc. reported its financial results for Q2 2023, highlighting ongoing enrollment in Phase 1 studies of its drug candidate NUV-868. The company maintains a robust cash position of $630.9 million and intends to submit an IND for its first Drug-Drug Conjugate by the end of the year. Additionally, a new oncology-focused Scientific Advisory Board has been established to guide future research. Despite a net loss for the quarter, Nuvation Bio is actively progressing its clinical pipeline in oncology.

May 4, 2023

Nuvation Bio Reports First Quarter 2023 Financial Results and Provides Business Update Enrollment ongoing in the Phase 1b study of NUV-868 in combination with olaparib or enzalutamide Enrollment ongoing in the Phase 1 mo

Nuvation Bio reported its first quarter 2023 financial results, highlighting ongoing enrollment in Phase 1 studies for its drug candidate NUV-868. The company maintains a strong balance sheet with $646.6 million in cash and equivalents. However, it also reported a net loss of $21.7 million, a slight increase from the previous year. The company anticipates submitting an IND for its first drug-drug conjugate clinical candidate by the end of 2023, continuing its efforts in oncology.

Mar 15, 2023

Nuvation Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Initiated both dosing regimens of the Phase 1b study of NUV-868 in combination with olaparib or enzalutamide Dosing on

Nuvation Bio reported its financial results for Q4 and the full year of 2022, highlighting the initiation of both dosing regimens for its Phase 1b study of NUV-868 in combination with olaparib or enzalutamide. The company has a strong balance sheet with $661 million in cash and equivalents, and plans to submit an IND for its first clinical candidate from a new Drug-Drug Conjugate platform by the end of 2023. However, Nuvation Bio reported an increased net loss of $104.2 million for the year, reflecting ongoing financial challenges amidst its clinical advancements.

Mar 2, 2023

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN RE NUVATION BIO INC. ) C.A. No. 2023-__-_ ) VERIFIED PETITION FOR RELIEF PURSUANT TO 8 DEL. C. 205 Petitioner Nuvation Bio Inc. ( Nuvation or the Company ), by and

Nuvation Bio Inc. has filed a petition with the Delaware Court of Chancery to validate its New Certificate of Incorporation and ensure the legitimacy of shares issued under it. This legal action arises from uncertainties created by the court's previous ruling in Garfield v. Boxed, which questioned the voting requirements for amendments in corporate governance. The company asserts that it received the necessary shareholder approval, despite not explicitly soliciting a separate vote from Class A shares. This petition aims to mitigate potential risks of irreparable harm related to their capital structure as they advance their oncology-focused biopharmaceutical initiatives.

Dec 23, 2022

▼ -5.9%on this news

Forward looking statements Certain statements included in this presentation (this "Presentation") that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United S

DRIVEN BY SCIENCE FOCUSED ON LIFE December 2022 Exhibit 99.1 Forward looking statements Certain statements included in this presentation (this "Presentation") that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the Unit

Nov 3, 2022

Privileged and confidential Nuvation Bio Reports Third Quarter 2022 Financial Results and Provides Business Update Dosing underway for Phase 1 monotherapy study of NUV-868 in advanced solid tumors Expect to initiate Phas

Privileged and confidential Nuvation Bio Reports Third Quarter 2022 Financial Results and Provides underway for Phase 1 monotherapy study of NUV-868 in advanced solid tumors initiate Phase 1b combination study of NUV-868 by the end of 2022 On track to nominate first clinical

Aug 4, 2022

Privileged and confidential Nuvation Bio Reports Second Quarter 2022 Financial Results and Provides Business Update Dosing underway for Phase 1 monotherapy study of NUV-868 in advanced solid tumors Strong financial posit

Nuvation Bio Reports Second Quarter 2022 Financial Results and Provides Business Update Dosing underway for Phase 1 monotherapy study of NUV-868 in advanced solid tumors Strong financial position provides cash runway through 2028; cash, cash equivalents and marketable securitie

Aug 1, 2022

▼ -9.8%on this newsshared move

Privileged and confidential Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program Company prioritizes NUV-868, its BD2 selective BET inhibitor currently in a Phase 1 dose escalation study in adva

Privileged and confidential Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program Company prioritizes NUV-868, its BD2 selective BET inhibitor currently in a Phase 1 dose escalation study in advanced solid tumors, and its novel small molecule Drug-Dru

Nuvation Bio Reports First Quarter 2022 Financial Results and Provides Business Update NUV-422 on track for initiation of multiple Phase 1b combination and Phase 2 monotherapy cohorts by the end of 2022 First patient dos

Nuvation Bio Reports First Quarter 2022 Financial Results and Provides Business Update NUV-422 on track for initiation of multiple Phase 1b combination and Phase 2 monotherapy cohorts by First patient dosed in Phase 1 study of NUV-868 for the treatment of solid On track to sel

Nuvation Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update FDA Fast Track Designation and multiple IND applications accepted for lead candidate NUV-422 Multiple milestones expec

Nuvation Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update FDA Fast Track Designation and multiple IND applications accepted for lead candidate Multiple milestones expected in 2022 for broad pipeline of potential product Strong balanc

Nov 10, 2021

Nuvation Bio Reports Third Quarter 2021 Financial Results and Provides Business Update Enrollment ongoing in phase 1/2 study of NUV-422 for the treatment of multiple difficult-to-treat cancers Strong balance sheet with c

Nuvation Bio Reports Third Quarter 2021 Financial Results and Provides Business Update Enrollment ongoing in phase 1/2 study of NUV-422 for the treatment of multiple difficult-to-treat cancers Strong balance sheet with cash, cash equivalents and marketable securities of $791.8

Nuvation Bio Reports Second Quarter 2021 Financial Results and Provides Business Update Ongoing enrollment in Phase 1/2 study of lead investigational compound NUV-422 for the treatment of adult patients with malignant gl

Nuvation Bio Reports Second Quarter 2021 Financial Results and Provides Business Update Ongoing enrollment in Phase 1/2 study of lead investigational compound NUV-422 for the treatment of adult patients with malignant gliomas; protocol amendment submitted to expand into additio

May 17, 2021

Nuvation Bio Reports First Quarter 2021 Financial Results and Provides Business Update Ongoing enrollment in Phase 1/2 study of NUV-422 in high-grade gliomas Strong balance sheet with cash, cash equivalents and marketabl

Nuvation Bio Reports First Quarter 2021 Financial Results and Provides Business Update Ongoing enrollment in Phase 1/2 study of NUV-422 in high-grade gliomas Strong balance sheet with cash, cash equivalents and marketable securities of $824.7million as of March 31, 2021 Previ

Oct 21, 2020

Nuvation Bio and Panacea Announce Business Combination Agreement, Creating a Publicly Listed Leader in Oncology Drug Development Leading institutional investors commit $500 million through concurrent equity investments U

Nuvation Bio and Panacea Announce Business Combination Agreement, Creating a Publicly Listed Leader in Oncology Drug Development Leading institutional investors commit $500 million through concurrent equity investments Upon completion of the business combination, over $850 m

Aug 21, 2020

Panacea Acquisition Corp. Announces the Separate Trading of its Shares of Class A Common Stock and Redeemable Warrants Commencing

Panacea Acquisition Corp. Announces the Separate Trading of its Shares of Class A Common Stock and Redeemable Warrants Commencing August 21, 2020 NEW YORK, NY, August 20, 2020 - Panacea Acquisition Corp. (NYSE: PANA.U) (the "Company," "us" or "our") today announced that, comme

Jul 6, 2020

PANACEA ACQUISITION CORP. INDEX TO FINANCIAL STATEMENTS PAGE Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of

PANACEA ACQUISITION CORP. INDEX TO FINANCIAL STATEMENTS PAGE Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of July 6, 2020 F-3 Notes to Financial Statement F-4 REPORT OF INDEPENDENT REGISTERED PUBLIC To the Stockholders and the Board of Directo

Jun 30, 2020